Navigation Links
CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG

Cell Therapeutics Inc (Seattle WA) has agreed to pay the US $10.5 millon to resolve allegations of the company's alleged illegal marketing// of the anti-cancer prescription drug Trisenox, the US Justice Department announced earlier this month.

According to the government's complaint, CTI promoted the drug for various uses that were unapproved by the US Food & Drug Administration (FDA).

The alleged "off-label" uses caused doctors to prescribe Trisenox to treat various forms of cancer for which the drug was neither approved by the FDA, nor proven to be either safe or effective. The government's suit alleged that because of the company's actions, physicians who prescribed Trisenox off-label unwittingly submitted false claims for reimbursement to the Medicare program from 2001-05. In 2005, CTI sold Trisenox to another company, and the drug's new owner halted CTI's misleading off-label promotion campaign.

"Cell Therapeutics essentially subverted a regulatory system designed to assure that patients receive only those drugs that have been proven to be effective for their illness," said Peter D. Keisler, Asst Attorney General for the Justice Dept's Civil Div.

Under the rules in effect at the time of the conduct in question, the complaint asserts that Medicare paid only for anti-cancer drugs when prescribed for FDA-approved uses, or uses that were determined to be medically accepted as published in certain specific pharmacological texts known collectively as the compendia. The government alleges that CTI knew that Trisenox was FDA-approved for only one type of cancer and was not listed as a medically accepted treatment in the compendia for any other condition. Nevertheless, the complaint states and claims that CTI falsely marketed the drug to doctors by suggesting that Trisenox was FDA-approved and listed as medically accepted in the compendia for other types of cancers.

"Cell Therapeutics enriched itself at taxpaye r expense by aggressively marketing this drug to doctors for use in treating certain types of cancers, even though the company knew that the drug had no proven medical benefit in the treatment of those cancers and had not been approved by the FDA for those uses," said Jeffrey C. Sullivan, US Attorney for the W District of WA.

In addition, the government's complaint alleges CTI used illegal kickbacks to induce physicians to prescribe Trisenox. Under sham "consulting agreements," physicians were paid $500-$1,000 to attend dinners or conferences on the off-label uses of Trisenox. These meetings were held at expensive resorts and restaurants. Doctors who wrote large numbers of prescriptions for Trisenox for off-label uses were asked to speak at various events for additional financial bonuses.

Source: BIOMEDICAL MARKET NEWSLETTER/M
'"/>




Related medicine news :

1. Mystery Surrounding Use Of Abortion Pill Yet To Be Resolved
2. Kenya Resolves to Fight Tuberculosis
3. Dispute in Findings about Radiation exposure
4. Radiographers Pay Parity Disputes Still Unresolved
5. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ANGELES (PRWEB) , ... October 12, 2017 , ... ... Parsa Mohebi Hair Restoration, has recently contributed a medical article to the newly ... on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: